Cover Image
Market Research Report

Remicade (Infliximab) Biosimilar Clinical Trial Insight

Published by PNS Pharma Product code 374508
Published Content info 50 Pages
Delivery time: 1-2 business days
Back to Top
Remicade (Infliximab) Biosimilar Clinical Trial Insight
Published: October 17, 2016 Content info: 50 Pages

"Remicade (Infliximab) Biosimilar Clinical Trial Insight" report by PNS Pharma gives comprehensive clinical insight on 17 biosimilar version of Remicade drug in clinical pipeline. Currently there are 2 biosimilars in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 3 biosimilar version of Remicade are commercially available in India, Brazil and European countries for the treatment of Ankylosing spondylitis, Crohn's disease and Rheumatoid Arthritis. The patent on Remicade is set to expire in 2018 for US and 2017 for rest of world.

Remicade is the trade name for infliximab which is a chimeric monoclonal antibody biologic drug, marketed by Janssen Biotech. Infliximab is used to fight against tumor necrosis factor alpha (TNF-α) to treat auto immune diseases such as rheumatoid arthritis. The drug is a purified form of recombinant DNA-derived human-mouse monoclonal antibodies consisting of mouse and human's heavy and light chain variable regions. It is a prescribed drug, approved by Food and Drug Association for the treatment of Crohn's disease, Pediatric Crohn's disease, Ulcerative colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing spondylitis and Plaque psoriatic.

FDA approved infliximab in September 2006, for chronic Plaque Psoriasis. Infliximab comes under the form of naturally occurring antibodies (anti-TNF bodies) with the ability to neutralize all forms of TNF. It is capable of breaking down of cell causing inflammatory process. Biological activities such as pro inflammatory cytokines, enhancement of leukocyte movement and increasing the release of adhesion molecules are attributed to TNF-α.

Infliximab is made up of human and mouse antibodies. It is an artificial antibody originally developed from mice. Due to human immune reaction to mouse proteins, the mouse common domains are replaced with human antibody domains. Infliximab is has main key components as human mouse antibody amino acids because of which is referred as chimeric monoclonal antibody.

Infliximab works by binding action of remicade with TNF-α. Playing a crucial role in auto immune systems, TNF-α is a chemical messenger. In the case of rheumatoid arthritis, infliximab works to prevent TNF-α by attaching to its receptor in the cell. Infliximab works by neutralizing the biological activity of TNF-α. It inhibits the functional activity of wide variety utilizing human fibroblasts, endothelial cells, neutrophils, B and T-lymphocytes and epithelial cells. Though, the biological responses through which remicade exert clinical effects in the body are still considered to be unknown.

Remicade is necessarily induced intravenously because of the fact that the drug can be destroyed by the digestive system of a patient in case given by mouth. The dosages are typically administered by infusion within the interval of 6 to 8 weeks. The initial process involves the 3 starter infusions over first 6 weeks, followed by 2 more after next 2 and 4 weeks. Along with remicade, patients are prescribed with a particular amount of medication, depending upon the patient's weight to reduce its side effects

Similar to other TNF inhibitors, infliximab is an expensive drug costing range from US$ 1300 - US$ 2500 for every dosage. It is manufactured as a sterile lyophilized white freeze dried powder which necessarily requires administration and reconstitution by a health care professional. Due to this need of extra care during treatment and infusion of remicade, it is a part of major health insurances.

Table of Contents

Table of Contents

1. Remicade (Infliximab) Clinical Insight

  • 1.1 Clinical Introduction
  • 1.2 Company Partnerships & Agreements
  • 1.3 Patent Analysis by Indication
  • 1.4 Phase of Development
  • 1.5 Designated Orphan Status by Indication & Country
  • 1.6 Brand Names by Country/Region

Remicade Biosimilars Clinical Insight by Company

2. Infliximab Biosimilar - Amgen

  • 2.1 Clinical Insight
  • 2.2 Development Timeline
  • 2.3 Phase of Development

3. Infliximab Biosimilar - Axxo

  • 3.1 Clinical Insight
  • 3.2 Phase of Development

4. Infliximab Biosimilar - Biocad

  • 4.1 Clinical Insight
  • 4.2 Development Timeline
  • 4.3 Phase of Development

5. Infliximab Biosimilar - Bionovis/The Instituto Vital Brazil

  • 5.1 Clinical Insight
  • 5.2 Development Timeline
  • 5.3 Phase of Development

6. Infliximab Biosimilar - BioXpress Therapeutics

  • 6.1 Clinical Insight
  • 6.2 Phase of Development

7. Infliximab Biosimilar - Celltrion

  • 7.1 Clinical Insight
  • 7.2 Development Timeline
  • 7.3 Patent Analysis
  • 7.4 Phase of Development

8. Infliximab Biosimilar - Curaxys

  • 8.1 Clinical Insight
  • 8.2 Phase of Development

9. Infliximab Biosimilar - Genor Biopharma

  • 9.1 Clinical Insight
  • 9.2 Development Timeline
  • 9.3 Phase of Development

10. Infliximab Biosimilar - Harvest Moon Pharmaceuticals

  • 10.1 Clinical Insight
  • 10.2 Development Timeline
  • 10.3 Phase of Development

11. Infliximab Biosimilar - LG Life Sciences

  • 11.1 Clinical Insight
  • 11.2 Phase of Development

12. Infliximab Biosimilar - Merck & Co/Samsung Bioepis

  • 12.1 Clinical Insight
  • 12.2 Development Timeline
  • 12.3 Phase of Development

13. Infliximab Biosimilar - Nanogen Biopharmaceutical

  • 13.1 Clinical Insight
  • 13.2 Phase of Development

14. Infliximab Biosimilar - Nichiiko Pharmaceutical/Aprogen

  • 14.1 Clinical Insight
  • 14.2 Development Timeline
  • 14.3 Phase of Development

15. Infliximab Biosimilar - Pfizer

  • 15.1 Clinical Insight
  • 15.2 Development Timeline
  • 15.3 Phase of Development

16. Infliximab Biosimilar - Reliance Life Sciences

  • 16.1 Clinical Insight
  • 16.2 Development Timeline
  • 16.3 Phase of Development

17. Infliximab Biosimilar - Shanghai CP Guojian Pharmaceutical

  • 17.1 Clinical Insight
  • 17.2 Development Timeline
  • 17.3 Phase of Development

18. Infliximab Biosimilar - Therapeutic Proteins International

  • 18.1 Clinical Insight
  • 18.2 Phase of Development

List of Tables

  • Table 2-1: Amgen Infliximab Biosimilar by Indication & Phase
  • Table 3-1: Axxo Infliximab Biosimilar by Indication & Phase
  • Table 4-1: Biocad Infliximab Biosimilar by Indication & Phase
  • Table 5-1: Bionovis/The Instituto Vital Brazil Infliximab Biosimilar by Indiaction & Phase
  • Table 6-1: BioXpress Therapeutics Infliximab Biosimilar by Indication & Phase
  • Table 7-1: Celltrion Infliximab Biosimilar by Indication & Phase
  • Table 8-1: Curaxys Infliximab Biosimilar by Indication & Phase
  • Table 9-1: Genor Biopharma Infliximab Biosimilar by Indication & Phase
  • Table 10-1: Harvest Moon Pharmaceuticals Infliximab Biosimilar by Indication & Phase
  • Table 11-1: LG Life Sciences Infliximab Biosimilar by Indication & Phase
  • Table 12-1: Merck & Co/Samsung Bioepis Infliximab Biosimilar by Indication & Phase
  • Table 13-1: Nanogen Biopharmaceutical Infliximab Biosimilar by Indication & Phase
  • Table 14-1: Nichiiko Pharmaceutical/Aprogen Infliximab Biosimilar by Indication & Phase
  • Table 15-1: Pfizer Infliximab Biosimilar by Indication & Phase
  • Table 16-1: Reliance Life Sciences Infliximab Biosimilar by Indication & Phase
  • Table 17-1: Shanghai CP Guojian Pharmaceutical Infliximab Biosimilar by Indication & Phase
  • Table 18-1: Therapeutic Proteins International Infliximab Biosimilar by Indication & Phase
Back to Top